Document is current

Any future updates will be listed below

Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1186/s12916-024-03644-0

Published Online: 2024-09-20

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark